Karaman Erdur, SevilKulaç Karadeniz, DeryaKocabora, Mehmet SelimÖzsütçü, MustafaGülkılık, İbrahim GökhanDemirci, GöktuğEliaçık, Mustafa10.07.20192019-07-1010.07.20192019-07-102015Karaman Erdur, S., Kulaç Karadeniz, D., Kocabora, M. S., Özsütçü, M., Gülkılık, İ. G., Demirci, G. ve Eliaçık, M. (2015). Ocular surface and tear parameters in patients with chronic hepatitis c at initial stages of hepatic fibrosis. Eye and Contact Lens, 41(2), 117-120. https://dx.doi.org/10.1097/ICL.00000000000000791542-23211542-233Xhttps://dx.doi.org/10.1097/ICL.0000000000000079https://hdl.handle.net/20.500.12511/2522WOS: 000350136600012PubMed ID: 25503914Purpose: The aim of this study was to evaluate changes in ocular surface and tear function parameters in chronic hepatitis C at initial stages of hepatic fibrosis. Methods: Thirty-one patients with biopsy-proven chronic hepatitis C and 31 age-and sex-matched healthy control subjects without systemic hepatitis C infection were examined with the Ocular Surface Disease Index (OSDI) questionnaire, Schirmer I, tear film break-up time, and scoring of ocular surface fluorescein and Rose Bengal staining using modified Oxford and van Bijsterveld scoring systems, respectively. Results: All ocular surface parameters, except OSDI and corneal staining scores, were significantly worse in hepatitis C group. The control group had greater OSDI scores than the hepatitis C group, but there was no statistically important difference. In subgroup analysis, progression of hepatic fibrosis was found to be correlated strongly with decreased Schirmer test I, increased OSDI, lid parallel conjunctival folds, conjunctival, and corneal staining scores. Conclusion: Patients with chronic hepatitis C were more likely to exhibit severe ocular surface damage and signs of dry eye.eninfo:eu-repo/semantics/embargoedAccessTear FilmHepatitis CDry Eye DiseaseOcular SurfaceOcular surface and tear parameters in patients with chronic hepatitis c at initial stages of hepatic fibrosisArticle41211712010.1097/ICL.0000000000000079Q3Q2